Recently, studies have demonstrated that glycolytic reprogramming in CAFs is involved in tumor progression and heterogeneity in breast cancer via different modes, such as cancer cell-secreted exo-miR-105 promoting MYC expression, cancer cells overexpressing ITGB-4; and normal fibroblasts overexpressing HIF-1α [66–68]. Here, ITGB4 is linked to cancer.